Results 211 to 220 of about 73,182 (252)

Mapping the immune microenvironment of <i>KIT</i>- and <i>PDGFRA</i>-mutant GISTs reveals genotype-specific immune infiltration and TKI-induced remodeling. [PDF]

open access: yesFront Immunol
Costa A   +13 more
europepmc   +1 more source

Advances in immunotherapy for gastrointestinal malignancies. [PDF]

open access: yesFront Immunol
Liu B   +6 more
europepmc   +1 more source

Improving Anti-CTLA-4 Therapies through Peptide Masking and Fragment Crystallizable Non-fucosylation: Preclinical Characterization of Three Novel Antibodies. [PDF]

open access: yesClin Cancer Res
Jhatakia A   +31 more
europepmc   +1 more source

Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade [PDF]

open access: yesCell, 2018
CTLA-4 immune checkpoint blockade is clinically effective in a subset of patients with metastatic melanoma. We identify a subcluster of MAGE-A cancer-germline antigens, located within a narrow 75 kb region of chromosome Xq28, that predicts resistance uniquely to blockade of CTLA-4, but not PD-1.
Jedd D. Wolchok   +2 more
exaly   +5 more sources
Some of the next articles are maybe not open access.

Related searches:

B70 antigen is a second ligand for CTLA-4 and CD28

Nature, 1993
The membrane antigen B7/BB1 (refs 1, 2) is expressed on activated B cells, macrophages and dendritic cells, and binds to a counter-receptor, CD28, expressed on T lymphocytes and thymocytes. Interaction between CD28 and B7 results in potent costimulation of T-cell activation initiated through the CD3/T-cell receptor complex.
M, Azuma   +6 more
openaire   +2 more sources

CTLA-4 blockade of antigen-induced cell death

Blood, 2001
AbstractWhile cytotoxic T lymphocyte antigen–4 (CTLA-4) negatively regulates T-cell receptor (TCR)–driven interleukin (IL)–2 production and proliferation, little is known regarding whether the coreceptor has the capacity to inhibit other events, such as Fas ligand (FasL) expression and antigen-induced cell death (AICD).
S, da Rocha Dias, C E, Rudd
openaire   +2 more sources

Enhanced antitumor immunity by fusion of CTLA-4 to a self tumor antigen

Blood, 2000
The idiotypic determinant (Id) of the immunoglobulin expressed by a B-cell malignancy can serve as an effective tumor-specific antigen but is only weakly immunogenic. This study demonstrates that the immunogenicity of the tumor Id protein can be dramatically increased by directing it to antigen-presenting cells (APCs). Cytotoxic T-lymphocyte antigen 4 (
T H, Huang   +6 more
openaire   +2 more sources

Diagnostic Performance of CTLA-4, Carcinoembryonic Antigen and CYFRA 21-1 for Malignant Pleural Effusion

open access: yesPostgraduate Medicine, 2017
Objectives: The diagnosis of malignant pleural effusion (MPE) remains a clinical challenge. As a negative regulator of T-cell activation, cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) has been associated with many malignant diseases. However, there is limited data about the relationship between CTLA-4 and MPE.
Fuqiang Wen, Yongchun Shen, Ni Zeng
exaly   +3 more sources

Influence of cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms in periodontitis

Archives of Oral Biology, 2012
Persistent host inflammatory immune response against the pathogens results in the destruction of periodontal tissues. Cytotoxic T lymphocyte antigen 4 (CTLA-4) is a particularly important molecule in down-regulating T-cell expansion and cytokine production.
B, Houshmand, A, Rafiei, M, Hajilooi
openaire   +2 more sources

Home - About - Disclaimer - Privacy